BIIB BIOGEN INC.

Price Chart

Executive Summary

Wells Fargo double upgraded Biogen (BIIB) from Equal-Weight to Overweight on April 20, 2026, raising the price target to $250 from $200, implying 31.2% upside from the current $190.56. The firm has a 55% accuracy rate on 6,035 calls with a 3.6% average return, placing it in the average range among covering firms. Consensus is mixed: 24 of 43 analysts rate Buy (56%), 18 Hold (42%), 1 Sell (2%), with a mean target of $219.27 (15.1% upside). The new $250 PT is above the consensus mean and median ($215), but below the high of $300. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days, though EPS revisions have been negative for the current quarter (9 down, 0 up) and current year (10 down, 0 up). Insider trades show no activity, but institutional moves are mixed: Norges Bank initiated a $464M position and FMR doubled its stake (+632%), while Wells Fargo itself trimmed its own position (-32.3%). Short interest is elevated at 66.8% of float, suggesting heavy bearish positioning. The next earnings report is due July 29, 2026, about 100 days out — not imminent. The double upgrade from a mid-tier accuracy firm with a PT above consensus is a moderately bullish signal, but the negative EPS revision trend and high short interest create a tug-of-war. Bottom line: the call is directionally bullish but lacks strong conviction from other signals.

Impact Score

Consensus & Targets

Consensus among 43 analysts: 9 Strong Buy, 15 Buy (56% total Buy), 18 Hold (42%), 1 Sell (2%). The consensus is tilted bullish but with a substantial hold contingent, reflecting uncertainty. Wells Fargo's Overweight aligns with the majority Buy view, but the double upgrade is more aggressive than the average stance.

Current price: $190.56. Mean target: $219.27 (15.1% upside). Median: $215 (12.8% upside). High: $300 (57.4% upside). Low: $150 (21.3% downside). Wells Fargo's $250 PT is above the mean and median, ranking in the upper quartile of targets, indicating above-consensus conviction.

Recent Analyst Activity

30-day analyst activity: 1 upgrade (Wells Fargo), 0 downgrades. EPS revisions are negative: current quarter EPS estimates have 9 downward revisions vs 0 upward in the last 30 days; current year has 10 down vs 0 up. However, next year (+1y) shows 8 up vs 1 down, suggesting a potential inflection. The near-term negative trend contrasts with the bullish analyst action.

Firm Track Record — Wells Fargo

Wells Fargo accuracy: 55% on 6035 calls | avg return: 3.6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Wells Fargo has a 55% accuracy rate on 6,035 calls with a 3.6% average return, placing it in the average range among covering firms. Top-tier firms on BIIB include Jefferies (100% on 2 calls, 13% avg return) and Morgan Stanley (83% on 6 calls, 5.5% avg return). Bottom-tier: Mizuho (33% on 3 calls, -5% avg return) and Oppenheimer (33% on 3 calls, -0.4% avg return). Wells Fargo's track record is not exceptional, reducing the signal's weight.

Earnings Estimates

Next earnings: Jul 29, 2026

Cross-Platform Signals

Insider trades: none reported. Congressional trades: none. Institutional moves: Norges Bank initiated a $464M position (new), FMR LLC doubled its stake (+632% to $1.66B) — strong bullish institutional signals. However, Wells Fargo itself trimmed its position (-32.3%), and Renaissance Technologies cut (-58.6%). UBS added (+35.1%). Short interest is very high at 66.8% of float, indicating heavy bearish positioning that could fuel a squeeze if positive catalysts emerge. The institutional buying from Norges and FMR converges with the bullish analyst call, while the firm's own trim and high short interest diverge.

Documents Analyzed

Report based on filing metadata.

US Market Status